Sobi announces positive results from phase 3 study of Doptelet® for treatment of children and adolescents with ITP
· The primary endpoint was met, confirming the efficacy and safety of avatrombopag (Doptelet®) in treating children and adolescents with ITP · avatrombopag is widely approved for the treatment of adults with ITP; AVA-PED-301 data will support global regulatory filings to expand to children and adolescents with ITPSobi® today announced positive results from the AVA-PED-301 study (NCT04516967 ), evaluating the efficacy and safety of avatrombopag (Doptelet) for the treatment of